Pfizer reports positive Phase 2 infant data for next-gen pneumococcal vaccine
Pfizer (NYSE:PFE) disclosed preliminary data from its Phase 2 clinical trial evaluating PF-07872412, an investigational 25-valent pneumococcal conjugate vaccine candidate designed for pediatric use.






_1403591_640x360_2500727875865-640x360.webp&w=3840&q=75)
_1403583_640x360_2500729923857-640x360.webp&w=3840&q=75)
_1403578_640x360_2500728899754-640x360.webp&w=3840&q=75)

_1403567_640x360_2500736067528-640x360.webp&w=3840&q=75)
_1403538_640x360_2500730435537-640x360.webp&w=3840&q=75)